Ownership and insider activity for GeneDx Holdings Corp. (WGS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
Price
| Price | $76.27 |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $108.1M | $400.6M | $137.4M | $99.7M | $85.2M | $105.0M |
| Short-term Investments | 0 | 0 | 0 | $30.5M | $56.0M | $66.3M |
| Receivables | $32.3M | $26.6M | $43.3M | $32.8M | $37.6M | $74.4M |
| Inventory | $25.0M | $33.5M | $13.7M | $8.8M | $10.7M | $14.0M |
| Total Current Assets | $174.1M | $483.5M | $212.6M | $182.3M | $198.0M | $268.3M |
| Property, Plant & Equipment | $63.1M | $62.7M | $84.3M | $59.4M | $58.5M | $69.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | $13.5M |
| Intangible Assets | 0 | 0 | $186.7M | $172.6M | $158.6M | $168.5M |
| Total Assets | $251.6M | $554.1M | $545.3M | $418.8M | $419.4M | $570.2M |
| Accounts Payable | $26.7M | $44.7M | $46.0M | $10.2M | $8.0M | $2.5M |
| Short-term Debt | $3.5M | $3.4M | $10.9M | $497,000 | 0 | $8.9M |
| Total Current Liabilities | $73.4M | $101.3M | $144.3M | $58.8M | $54.8M | $108.9M |
| Long-term Debt | $19.0M | $11.0M | $6.2M | $52.7M | $51.9M | $87.0M |
| Total Liabilities | $247.3M | $166.0M | $291.6M | $190.7M | $174.1M | $262.0M |
| Retained Earnings | -$330.1M | -$575.4M | -$1.12B | -$1.30B | -$1.35B | -$1.37B |
| Total Equity | $4.4M | $388.1M | $253.7M | $228.0M | $245.2M | $308.2M |
| Total Debt | $43.3M | $32.8M | $77.1M | $119.8M | $116.2M | $151.9M |
| Net Debt | -$64.9M | -$367.7M | -$60.3M | -$10.4M | -$25.0M | -$19.3M |
| Working Capital | $100.7M | $382.3M | $68.3M | $123.5M | $143.2M | $159.4M |
Financial Health
| Debt / Equity | 0.69 |
| Current Ratio | 3.30 |
Profitability
| Return on Equity | -38.72% |
| Return on Invested Capital | -14.69% |
| Return on Assets | -22.09% |
| Gross Margin | 68.20% |
| Operating Margin | -13.34% |
| Net Margin | -23.40% |
Related companies: HNGE · IMVT · KYMR · NAMS · OPCH · OSCR
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of WGS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks